Bayer has launched a partnership with CRISPR Therapeutics.
The companies agreed to form Casebia Therapeutics in December 2015. It officially started operations today, August 19, at its base in Cambridge, Massachusetts.
The aim of the venture is to discover, develop and commercialise new breakthrough therapeutics to cure blood disorders, blindness, and congenital heart diseases.
Axel Bouchon, CEO of Casebia, said: “We are excited to engage the broader life science community in Boston now through Casebia.”
He added: “As we establish and grow Casebia’s therapeutic programmes, this new location will provide us with state-of-the-art infrastructure, access to the vibrant biotech environment of the Kendall Square area, and facilitate close collaboration with CRISPR Therapeutics.”